EP. 1: Overview of Huntington Disease
Watch
EP. 2: Genetic Testing and the Moral Dilemma of Testing
EP. 3: Economic Burden and Education on Huntington
EP. 4: Treatment Plan With Symptomatic Care and Patient Education
EP. 5: Emerging Treatment Options for Huntington Disease
EP. 6: Defining Rare Diseases and Orphan Drug Act
EP. 7: Spinal Muscular Atrophy (SMA) and Types of SMA
EP. 8: Patient Perspective and Payer Perspective of SMA
EP. 9: Payer Diagnostic Criteria and Prior Authorization of SMA
EP. 10: Prior Authorization and Payer Test Coverage of SMA
EP. 11: Diagnostic Tests and Scales of SMA
EP. 12: Economic Burden and Challenges of Trial of SMA
EP. 13: Treatment Goals and Multidisciplinary Management of SMA
EP. 14: Approval of Nusinersen for SMA
EP. 15: ENDEAR Study, Patient Factors, and Drug Approval Criteria
EP. 16: Knowledge Among Payers and Payer Requirements for Rare Disease
EP. 17: Challenges of Payer Criteria and Cost of Therapy for SMA
EP. 18: Payer Perspective and Value of Treatment of SMA
EP. 19: Zolgensma and the START Trial for SMA
EP. 20: Risdiplam and Final Thoughts
